Several clinical trials are ongoing that are focused on neurocognitive outcome in TSC based on identified risk factors, for example, using mammalian target of rapamycin (mTOR) inhibitors that target the downstream effect of the primary mutation (ClinicalTrials.gov Identifier: NCT01289912), through to parent‐based intervention (NCT03422367), and identification of EEG biomarkers of early versus delayed vigabatrin treatment in infants with TSC (NCT02849457). Here, MTOR is linked to tuberous sclerosis.